VP of Platform
Earli Inc
Redwood City, California, United States
I am Badri Ananthanarayanan, PhD, currently serving as VP of Platform at Earli Inc. I believe that breakthrough science requires deep engagement with the broader community, and that shared scientific goals can bring people together to solve the challenges facing our field, and thereby make real progress – despite having divergent individual and commercial obligations. This belief drove my interest in expanding my participation in the CRS GDGE focus group and serving on its board. I am presently the VP of R&D Platform at Earli and lead a team of brilliant scientists developing non-viral DNA-LNP products for Earli’s cancer-activated gene expression platform. I have initiated and led 6+ active collaborations with well-known delivery science groups (both academic and biotech) and am a key participant in scientific advisory board meetings, investor due diligence, BD/partnering meetings, etc. I have helped translate 2 non-viral DNA-based programs into Phase 1/2 human clinical studies in oncology and have also contributed to preclinical development of AAV-based gene therapy programs in rare disease. Before my biotech career, I investigated lipopeptide self-assembly for my PhD in Chemical Engineering at UC Santa Barbara, and elucidated mechanisms of cancer and stem cell mechanobiology during my postdoc tenure at UC Berkeley.
Disclosure information not submitted.
Gene Delivery and Gene Editing I
Tuesday, July 9, 2024
3:30 PM – 5:30 PM CET
